CRXT Clarus Therapeutics Bullish ReversalCRXT Clarus Therapeutics had 3 green days after its sell-off to all time low.
This should signal a reversal pattern.
Clarus Therapeutics has the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions called JATENZO.
The fist target is the $1.1 private placement offering price and then the $2.10 resistance.
Few months ago they had another private placement at $4.96 per unit, so we can take that into c
CLong

